Pharsight

Incyte Corp patents expiration

1. Jakafi patents expiration

JAKAFI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9814722 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Dec, 2026

(3 years from now)

US9814722

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(3 years from now)

US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(3 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

US8829013 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

US10016429 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

US7598257

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Jun, 2028

(4 years from now)

US8415362

(Pediatric)

INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2028

(4 years from now)

US10016429

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8829013

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8822481

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8722693

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 22, 2028
New Indication (I) Sep 22, 2024
M (M) Dec 19, 2025
Pediatric Exclusivity (PED) Mar 22, 2029

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 16 November, 2011

Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For treatment of polycythemia vera (pv) in patients who have had an inadequate respons...

Dosage: TABLET;ORAL

How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage

JAKAFI family patents

Family Patents

2. Opzelura patents expiration

OPZELURA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(4 years from now)

US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(4 years from now)

US8722693 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639310 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Dec, 2026

(3 years from now)

US9974790 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Dec, 2026

(3 years from now)

US9974790

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
Jun, 2027

(3 years from now)

US9079912

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Jun, 2027

(3 years from now)

US10639310

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2027

(3 years from now)

US8822481 INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

US10610530 INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Jun, 2028

(4 years from now)

US7598257

(Pediatric)

INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Jun, 2028

(4 years from now)

US8415362

(Pediatric)

INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Jun, 2028

(4 years from now)

US8822481

(Pediatric)

INCYTE CORP Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US10610530

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US8722693

(Pediatric)

INCYTE CORP Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Dec, 2028

(5 years from now)

US11219624 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(7 years from now)

US10758543 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(7 years from now)

US11590136 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(7 years from now)

US10869870 INCYTE CORP Topical formulation for a JAK inhibitor
May, 2031

(7 years from now)

US11571425 INCYTE CORP NA
May, 2031

(7 years from now)

US11219624

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US10758543

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US10869870

(Pediatric)

INCYTE CORP Topical formulation for a JAK inhibitor
Nov, 2031

(8 years from now)

US11590138 INCYTE CORP Topical treatment of vitiligo by a jak inhibitor
Jun, 2040

(16 years from now)

US11510923 INCYTE CORP Ruxolitinib formulation for reduction of itch in atopic dermatitis
Sep, 2040

(16 years from now)

US11590137 INCYTE CORP Ruxolitinib formulation for reduction of itch in atopic dermatitis
Sep, 2040

(16 years from now)

US11602536 INCYTE CORP Topical treatment of vitiligo by a JAK inhibitor
May, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 21, 2024
New Indication (I) Jul 18, 2025
Pediatric Exclusivity (PED) Jan 18, 2026

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Market Authorisation Date: 21 September, 2021

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...

Dosage: CREAM;TOPICAL

More Information on Dosage

OPZELURA family patents

Family Patents

3. Pemazyre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(9 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(15 years from now)

US11628162 INCYTE CORP Methods of treating cancer with an FGFR inhibitor
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Aug 26, 2029
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic